- Compounded semaglutide and Ozempic are different products. Ozempic is FDA-approved; compounded preparations are not FDA-approved or reviewed by FDA before marketing.
- They differ in who makes them. Ozempic is manufactured by Novo Nordisk and FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies under FDA Section 503A and 503B oversight.
- Cash prices vary by dose, insurance, savings eligibility, pharmacy, and provider program. Compare current all-in quotes rather than older list-price ranges.
- The FDA resolved the semaglutide injection shortage in February 2025. Compounding rules are now narrower than they were during the shortage.
- Safety depends on the pharmacy. 503B-designated outsourcing facilities follow FDA-inspected manufacturing standards. Always verify your pharmacy's credentials before starting treatment.
What is the difference between compounded semaglutide and Ozempic?
Ozempic is an FDA-approved Novo Nordisk drug product. Compounded semaglutide is a different preparation made by a licensed compounding pharmacy for a patient-specific medical need. Compounded products are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
If you have searched for weight loss treatment in the past few years, you have almost certainly come across both terms. Ozempic became a cultural shorthand for GLP-1 medication broadly. Compounded semaglutide emerged as a lower-cost alternative when the brand-name versions became difficult to obtain or afford. Understanding what makes them alike and what makes them different is essential before making a decision about your care.
The confusion is understandable. Marketing, media coverage, and social media discussion often blur the lines. This article gives you a clear, factual breakdown based on the clinical and regulatory record, not advertising.
Are they the same medication?
No. They may use semaglutide as an active ingredient, but they are not the same drug product. FDA has specifically identified claims that a compounded GLP-1 drug is “the same as” an FDA-approved drug as a warning sign. Ozempic has an FDA-reviewed formulation, manufacturing process, delivery system, labeling, and dosing instructions; a compounded preparation does not carry that product approval.
Compounded semaglutide may be clinically appropriate for a patient whose medical needs cannot be met by an FDA-approved drug, but the prescribing provider must evaluate that need. Patients should also confirm the ingredient form, concentration, dosing units, storage instructions, and dispensing pharmacy.
The meaningful differences are not pharmacological. They are regulatory, manufacturing-related, and economic. Ozempic goes through Novo Nordisk's controlled manufacturing process, FDA approval review, and proprietary pen delivery system. Compounded semaglutide is prepared in smaller batches by a licensed pharmacy, typically supplied as a vial with a syringe for self-injection, and does not carry the FDA-approved label that Ozempic does.
FDA-approved and compounded semaglutide products follow different regulatory and manufacturing pathways. Ask your provider which product is being prescribed and why it is appropriate for you.
Why does compounded semaglutide exist?
Compounding can address an individual patient's medical need when an FDA-approved product cannot meet that need. During prior shortages, federal policy also allowed broader temporary compounding under specific conditions.
The shortage problem
Ozempic was first approved by the FDA in December 2017 for type 2 diabetes management. When broader awareness of its weight loss effects spread rapidly in 2022 and 2023, demand outpaced Novo Nordisk's manufacturing capacity. Both Ozempic and Wegovy appeared on the FDA's Drug Shortage List, a formal designation that reflects documented supply disruptions in the U.S. market.[2]
The FDA declared the semaglutide injection shortage resolved in February 2025. After the agency's transition periods ended, compounders again became subject to restrictions on making products that are essentially copies of commercially available drugs. A patient-specific prescription may still support compounding when the prescriber documents a significant clinical difference for that patient, subject to current federal and state requirements.[3]
Because FDA policy and court orders can change, availability should be confirmed with your provider and dispensing pharmacy at the time of prescribing.
The cost problem
Out-of-pocket cost can still be a barrier. Brand list prices, manufacturer self-pay programs, insurance coverage, and telehealth program prices change frequently. The useful comparison is the current all-in price for the exact product and dose you would receive, including visits, supplies, and shipping.
Kind MD displays its current program pricing before checkout. Manufacturer and pharmacy prices should be verified directly because older online price ranges may not reflect current savings programs or coverage.
Cost comparison: brand vs. compounded
The table below captures the full picture across three semaglutide products. Note that insurance variables can significantly alter out-of-pocket costs for brand-name medications in either direction.
| Feature | Compounded Semaglutide | Ozempic (Novo Nordisk) | Wegovy (Novo Nordisk) |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| FDA approved | Pharmacy-regulated (503A/503B) | Yes (type 2 diabetes) | Yes (weight management) |
| Manufacturer | Licensed compounding pharmacy | Novo Nordisk | Novo Nordisk |
| Cost per month | Varies by dose and program | Varies by coverage and savings eligibility | Varies by coverage and savings eligibility |
| Requires prescription | Yes | Yes | Yes |
| Insurance coverage | Rarely | Sometimes (diabetes diagnosis) | Sometimes |
| Supply shortages | Generally available | FDA shortage resolved | FDA shortage resolved |
| Dosing flexibility | Customizable by provider | Fixed dose pens | Fixed dose pens |
| Delivery format | Multi-dose vial with syringe | Pre-filled auto-injector pen | Pre-filled auto-injector pen |
A note on insurance
Insurance coverage for Ozempic typically requires a type 2 diabetes diagnosis. Wegovy coverage for weight management is more variable and depends heavily on your plan. Even with coverage, step-therapy requirements, prior authorization delays, and high deductibles mean many insured patients still pay substantial out-of-pocket costs for the brand-name products. For those patients, the all-in out-of-pocket cost of compounded semaglutide is often lower even without any insurance benefit applying.
Safety and quality: what to look for
The safety profile of compounded semaglutide depends heavily on the pharmacy preparing it. Not all compounding pharmacies operate at the same standard. Knowing how to evaluate a pharmacy is one of the most important steps in accessing compounded GLP-1 treatment safely.
What separates high-quality compounding pharmacies
The FDA regulates two categories of compounding pharmacy. Section 503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients pursuant to a valid prescription. Section 503B outsourcing facilities are a higher-tier designation: they undergo FDA inspections, follow current Good Manufacturing Practice (cGMP) standards similar to pharmaceutical manufacturers, and are permitted to compound larger quantities for office use in addition to individual prescriptions.[3]
Kind MD works with licensed U.S. pharmacies serving patients across all 50 states. The dispensing pharmacy and applicable oversight may vary by prescription and state. Ask which pharmacy will fill your prescription and how to verify its license.
Red flags to avoid
The growth of interest in compounded semaglutide has attracted some bad actors. The following are clear warning signs that a source is not operating safely or legally:
- No prescription required. All legitimate semaglutide, compounded or brand-name, requires a valid prescription from a licensed provider. Any source offering semaglutide without a prescription is operating illegally.
- Unusually low prices. Compounded semaglutide at a legitimate 503B facility has real costs. Prices below $100 per month should raise serious questions about ingredient sourcing and quality.
- "Research use only" labels. This language indicates the product is not pharmaceutical-grade and is not intended for human administration. Purchasing research-grade peptides to self-inject is dangerous and unregulated.
- No licensed prescriber involved. Telehealth companies that provide compounded semaglutide must connect you with a licensed provider who reviews your medical history before prescribing. Automated "click to buy" models without real provider review are a serious safety concern.
- Unverifiable pharmacy credentials. Legitimate compounding pharmacies are licensed by their state board of pharmacy and, in the case of 503B facilities, listed in the FDA's database of registered outsourcing facilities.
FDA status explained
The regulatory distinction between Ozempic and compounded semaglutide is real and worth understanding clearly, without overstating what it means in practice.
Ozempic's FDA approval
Ozempic (semaglutide 0.5mg, 1mg, and 2mg) received FDA approval in December 2017 for improving blood sugar control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.[5] Wegovy (semaglutide 2.4mg) received a separate FDA approval in June 2021 specifically for chronic weight management.[6]
FDA approval means the drug has been evaluated through a structured review process for safety, efficacy, and manufacturing quality. The approval is product-specific: it covers a particular formulation, at particular doses, from a particular manufacturer.
How compounding is regulated
Compounded medications are not FDA-approved. This is a consistent and accurate statement. It is also one that requires context. The FDA has overseen compounding pharmacy regulation for decades across all therapeutic categories. Compounded medications are legal, regulated, and widely used in oncology, pain management, hormone therapy, and pediatric care, among many other fields.
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act establish conditions for lawful compounding. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. They should be used only when a patient's medical needs cannot be met by an FDA-approved drug.[3]
The practical implication for patients is to verify the prescriber, pharmacy, ingredient form, concentration, dosing units, and storage instructions. Never buy a product labeled “research use only” or sold without a prescription.
Want to know if compounded semaglutide is right for your situation?
Start with the free quiz to explore treatment options with Kind MD.
Take the Free 2-Minute Quiz →Which one should you choose?
There is no universal answer. The right choice depends on your specific situation, including your insurance coverage, budget, availability in your area, and the recommendation of your licensed provider. Here is a practical framework for thinking it through.
Your insurance covers it with manageable co-pays. You have a type 2 diabetes diagnosis and prefer the FDA-approved label. You are already stable on a brand-name product and not facing cost barriers.
The brand-name cost is out of reach without insurance coverage. Brand-name products are unavailable or backordered. You want dosing flexibility as you titrate. You are starting treatment and want to confirm tolerability before committing to a higher-cost option.
A few other practical considerations worth knowing:
- Dosing flexibility. Compounded semaglutide can be prepared at custom concentrations, which gives your provider more granular control over your titration schedule. Brand-name pens come in fixed doses, which can make micro-adjustments more difficult.
- Administration. Compounded semaglutide is typically drawn from a vial with a syringe. Ozempic and Wegovy use pre-filled auto-injector pens, which many patients find more convenient. If needle handling is a concern, discuss it with your provider.
- Provider oversight matters more than the product choice. The clinical outcome of GLP-1 treatment depends far more on the quality of prescriber oversight than on whether you use the brand or compounded version. Regular check-ins, dose adjustments, and monitoring are what drive results and safety.
Kind MD prescribes compounded semaglutide from 503B-designated outsourcing facilities. Every patient is reviewed personally by a board-certified physician before any prescription is written. Our clinical team monitors your progress and adjusts your plan based on how your body responds, not a one-size protocol.
